Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (TSX:ONC)

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

PR Newswire 3 days ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

PR Newswire 12 days ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

PR Newswire April 24, 2025

Small-cap cancer therapy innovator raises $20M in flexible funding

Trevor Abes  April 11, 2025

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

PR Newswire April 10, 2025

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

PR Newswire April 10, 2025

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

PR Newswire March 7, 2025

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

PR Newswire February 25, 2025

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

PR Newswire February 19, 2025
View More News ››

Opinion & Analysis (TSX:ONC)

Buzz on the Bullboards: New Year, New Attractive Stocks

Omri Wallach January 9, 2020

Target Price Raised Ninefold on Biotech After Share Consolidation

Streetwise Reports June 6, 2018

Canadian Biotech comes back to life: A buyer's guide

Tony Pullen January 21, 2014
View More Opinion ››

Bullboard Posts (TSX:ONC)

Perhaps

I need to listen to some Matchbox Twenty. I hope we all get out of this unscathed.
CaseyL - 12 hours ago

Rocks in my pocket.....

I fell in the pool. I'm losing energy, breath and I need to get back up. My vision is starting to cut out. ONCY
CaseyL - 12 hours ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech&#xAE; to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Should read: "... cell (G&C) therapy like CAR-T ..."
Noteable - 15 hours ago

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Oncolytics Biotech&#xAE; to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Every Big Pharma I've named either has an immune checkpoint inhibitor, ADC, bispecific, small molecule like PARP or CDK4/6 inhibitor,...
Noteable - 15 hours ago

RE:RE:RE:IDLE THOUGHTS

Good luck to you as well. Hopefully ASCO and the long delayed AGM lead to interesting and exciting times.
fox7mf - 16 hours ago

RE:RE:IDLE THOUGHTS

Yes, perhaps; I still think this abstract will givea little more than your average one. GOBLET is  very exciting, and I think this...
pelaboost - 16 hours ago
View more Bullboard ››

Forge Resources Corp.

Forge Resources Corp.

Forge Resources Corp. is a junior exploration company. The Company is engaged in the business of the exploration and ...
View More »